Endocrine and metabolic complications in children and adolescents with Sickle Cell Disease: an Italian cohort study.
Adolescent
Anemia, Sickle Cell
/ complications
Anthropometry
Child
Child, Preschool
Cross-Sectional Studies
Endocrine System Diseases
/ etiology
Female
Human Growth Hormone
/ deficiency
Humans
Hypogonadism
/ etiology
Hypothyroidism
/ etiology
Insulin Resistance
Male
Severity of Illness Index
Vitamin D Deficiency
/ etiology
Children and adolescents
Endocrine complications
Metabolism
Sickle cell disease
Journal
BMC pediatrics
ISSN: 1471-2431
Titre abrégé: BMC Pediatr
Pays: England
ID NLM: 100967804
Informations de publication
Date de publication:
11 02 2019
11 02 2019
Historique:
received:
08
03
2018
accepted:
30
01
2019
entrez:
13
2
2019
pubmed:
13
2
2019
medline:
5
3
2020
Statut:
epublish
Résumé
Children with Sickle Cell Disease (SCD) show endocrine complications and metabolic alterations. The physiopathology of these conditions is not completely understood: iron overload due to chronic transfusions, ischemic damage, and inflammatory state related to vaso-occlusive crises may be involved. Aims of this study were to evaluate the growth pattern, endocrine complications, and metabolic alterations and to detect the relationship between these conditions and the SCD severity in affected children and adolescents. Fifty-two children and adolescents with SCD [38 homozygous sickle hemoglobin (HbSS) and 14 heterozygous sickle hemoglobin (HbSC); age range 3-18 years] were recruited. Anthropometric [height, body mass index (BMI), arm span, sitting height, target height (TH), and pubertal status] and laboratory [blood cell counts, hemolysis indices, metabolic and nutritional status indices and hormonal blood levels] data were evaluated. The SCD severity was defined according to hematological and clinical parameters. Height-SDS adjusted for TH and BMI-SDS were significantly higher in HbSC children than in HbSS ones. Forty-eight out of 52 patients (92%) had at least one metabolic and/or endocrine alteration: insufficiency/deficiency of vitamin D (84.7%), insulin resistance (11.5%), growth hormone deficiency (3.8%), subclinical hypothyroidism (3.8%), and hypogonadism (1.9%). Levels of vitamin D were significantly and negatively correlated with clinical indicators of the SCD severity. Subjects with HbSS genotype show significant lower levels of both insulin-like growth factor-1 (IGF-1) and insulin-like growth factor binding protein 3 than children with HbSC. In the study population IGF-1 values were significantly and positively correlated with Hb and negatively with lactate dehydrogenase. Metabolic alterations and endocrine complications are very common in children and adolescents with SCD. A regular follow-up is necessary to identify subjects at risk for complications to precociously start an appropriate treatment and to improve the quality of life of SCD patients.
Sections du résumé
BACKGROUND
Children with Sickle Cell Disease (SCD) show endocrine complications and metabolic alterations. The physiopathology of these conditions is not completely understood: iron overload due to chronic transfusions, ischemic damage, and inflammatory state related to vaso-occlusive crises may be involved. Aims of this study were to evaluate the growth pattern, endocrine complications, and metabolic alterations and to detect the relationship between these conditions and the SCD severity in affected children and adolescents.
METHODS
Fifty-two children and adolescents with SCD [38 homozygous sickle hemoglobin (HbSS) and 14 heterozygous sickle hemoglobin (HbSC); age range 3-18 years] were recruited. Anthropometric [height, body mass index (BMI), arm span, sitting height, target height (TH), and pubertal status] and laboratory [blood cell counts, hemolysis indices, metabolic and nutritional status indices and hormonal blood levels] data were evaluated. The SCD severity was defined according to hematological and clinical parameters.
RESULTS
Height-SDS adjusted for TH and BMI-SDS were significantly higher in HbSC children than in HbSS ones. Forty-eight out of 52 patients (92%) had at least one metabolic and/or endocrine alteration: insufficiency/deficiency of vitamin D (84.7%), insulin resistance (11.5%), growth hormone deficiency (3.8%), subclinical hypothyroidism (3.8%), and hypogonadism (1.9%). Levels of vitamin D were significantly and negatively correlated with clinical indicators of the SCD severity. Subjects with HbSS genotype show significant lower levels of both insulin-like growth factor-1 (IGF-1) and insulin-like growth factor binding protein 3 than children with HbSC. In the study population IGF-1 values were significantly and positively correlated with Hb and negatively with lactate dehydrogenase.
CONCLUSIONS
Metabolic alterations and endocrine complications are very common in children and adolescents with SCD. A regular follow-up is necessary to identify subjects at risk for complications to precociously start an appropriate treatment and to improve the quality of life of SCD patients.
Identifiants
pubmed: 30744584
doi: 10.1186/s12887-019-1423-9
pii: 10.1186/s12887-019-1423-9
pmc: PMC6371531
doi:
Substances chimiques
Human Growth Hormone
12629-01-5
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
56Références
Metabolism. 1997 Nov;46(11):1241-5
pubmed: 9361679
Arch Dis Child. 1969 Jun;44(235):291-303
pubmed: 5785179
Pediatr Hematol Oncol. 2012 Apr;29(3):261-6
pubmed: 22475302
J Trop Pediatr. 1992 Dec;38(6):307-13
pubmed: 1844090
N Engl J Med. 1994 Jun 9;330(23):1639-44
pubmed: 7993409
Blood. 2010 Apr 29;115(17):3447-52
pubmed: 20194891
J Pediatr Endocrinol Metab. 2007 Feb;20(2):211-8
pubmed: 17396438
Nutr J. 2016 Apr 30;15(1):46
pubmed: 27130184
Turk J Haematol. 2013 Mar;30(1):25-31
pubmed: 24385749
Lancet. 2010 Dec 11;376(9757):2018-31
pubmed: 21131035
Horm Res Paediatr. 2016;86(6):361-397
pubmed: 27884013
Arch Dis Child. 2000 Mar;82(3):204-8
pubmed: 10685921
Hematol Oncol Stem Cell Ther. 2016 Mar;9(1):1-7
pubmed: 26684919
Ann Trop Paediatr. 2008 Sep;28(3):165-89
pubmed: 18727846
Horm Res Paediatr. 2014;82(2):113-21
pubmed: 25011431
Drugs. 2012 May 7;72(7):895-906
pubmed: 22519940
Pediatrics. 2005 Apr;115(4):e500-3
pubmed: 15741351
Br J Haematol. 2006 Nov;135(4):574-82
pubmed: 17054676
J Clin Invest. 1985 Aug;76(2):470-3
pubmed: 3839801
Pediatr Res. 2007 May;61(5 Pt 1):607-13
pubmed: 17413865
J Pediatr Endocrinol Metab. 2004 Apr;17(4):601-6
pubmed: 15198291
Calcif Tissue Int. 2002 Feb;70(2):70-3
pubmed: 11870410
PLoS One. 2015 Mar 03;10(3):e0119908
pubmed: 25734582
Arch Dis Child. 1970 Dec;45(244):755-62
pubmed: 5491878
Am J Clin Nutr. 2002 Jun;75(6):1093-7
pubmed: 12036818
World J Clin Pediatr. 2016 Feb 08;5(1):25-34
pubmed: 26862499
Hemoglobin. 2017 Jul - Nov;41(4-6):230-233
pubmed: 29233055
Prog Cardiovasc Dis. 2013 Nov-Dec;56(3):261-9
pubmed: 24267433
Osteoporos Int. 2011 Jun;22(6):1745-53
pubmed: 20848081
Nat Clin Pract Endocrinol Metab. 2008 Feb;4(2):102-9
pubmed: 18212812
Br J Haematol. 2005 Aug;130(3):437-44
pubmed: 16042695
J Pediatr. 2004 Nov;145(5):622-7
pubmed: 15520761
Eur J Pediatr. 2012 Dec;171(12):1793-8
pubmed: 22949161
Am J Clin Nutr. 2002 Jul;76(1):218-25
pubmed: 12081838
J Clin Res Pediatr Endocrinol. 2010;2(3):100-6
pubmed: 21274322
Lipids Health Dis. 2010 Aug 27;9:91
pubmed: 20799970
J Trop Pediatr. 1999 Feb;45(1):23-30
pubmed: 10191589
Blood. 2005 Oct 1;106(7):2269-75
pubmed: 16172253
J Pediatr Hematol Oncol. 2001 Aug-Sep;23(6):357-63
pubmed: 11563770
J Trop Pediatr. 1995 Oct;41(5):285-9
pubmed: 8531260
Arch Dis Child. 1996 Jun;74(6):502-6
pubmed: 8758125
Pediatr Blood Cancer. 2014 Jan;61(1):34-9
pubmed: 24038856